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Cytotoxic T lymphocytes (CTL) are critical for lentivirus control including EIAV. Since CTL from most EIAV carrier horses
recognize Gag epitope clusters (EC), the hypothesis that carrier horses would have high functional avidity CTL to optimal epitopes in
Gag EC was tested. Twenty-two optimal EC epitopes were identified; two in EC1, six in EC2, and seven each in EC3 and 4.
However, only five of nine horses had high functional avidity CTL (11 nM) recognizing six epitopes in EC; four in relatively
conserved EC3; and one each in EC1 and 2. Horses with high functional avidity CTL had significantly more days since the last
clinical episode than horses with low avidity CTL, and this was not explained by analyzing duration of infection. Furthermore, there
was a significant inverse correlation between the CTL functional avidity of the nine horses and the days since the last clinical episode.
Gag CTL epitope escape variants were found in three horses, but only one of these was recognized by high functional avidity CTL.
Thus, not all carrier horses had high functional avidity CTL to Gag EC, but those that did had longer periods without disease
episodes.
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EIAV, a lentivirus, causes persistent infection in horses
that is initially characterized by recurrent viremia with
fever, thrombocytopenia, and anemia (Sellon et al., 1994).
Disease episodes are associated with viral antigenic
variants as defined by neutralizing antibody (Hussain et
al., 1987; Kono et al., 1973, 1976) and recently by CTL
(Mealey et al., 2003). However, in most infected horses,
disease episodes are eventually controlled within the first
6 to 12 months of infection, and a lifelong inapparent
carrier stage follows (Coggins, 1984). Immune responses
to EIAV are critical for termination of the initial viremia,0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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* Corresponding author. Fax: +1 509 335 8529.
E-mail address: mcguiret@vetmed.wsu.edu (T.C. McGuire).
1 Current address: Wisconsin Primate Research Center, Department of
Pathology, Laboratory of Medicine, University of Wisconsin, 1300
University Avenue Madison, WI 53706, USA.as shown by comparison of viremia between normal and
severe combined immunodeficient (SCID) foals which
lack functional T and B lymphocytes (Mealey et al.,
2001; Perryman et al., 1988). Based on accumulated data,
the protective immune responses for the control of EIAV
viremia include neutralizing antibody and CTL (Ham-
mond et al., 1997, 2000; Mealey et al., 2001, 2003;
Perryman et al., 1988; Zhang et al., 1998).
In HIV-1 and SIV infections, CTL responses correlate
with virus clearance (Kuroda et al., 1999; Ogg et al.,
1998). Depletion of CD8+ cells in SIV-infected macaques
demonstrate that these cells are required for SIV control
(Schmitz et al., 1999). Several experiments indicate that
CTL responses and not neutralizing antibody resolve early
episodes of viremia and clinical disease in EIAV-infected
horses (Carpenter et al., 1987; McGuire et al., 1994;
Mealey et al., 2003). Evaluation of CTL responses to HIV-
1 (Novitsky et al., 2002) and EIAV (Chung et al., 2004;
Zhang et al., 1998) demonstrates that Gag proteins are05) 228 – 239
Table 1
MHC class I haplotypes of EIAV-infected horses used for Gag CTL epitope
mapping
Horse no. MHC class I alleles
(Chung et al., 2003)
ELA-A haplotypes
H593 113, 114 A1a
H596 115, 116, 117, 118, 119 A4/W11
H601 Not done A1/W11
H610 111, 121, 122 A6a
H614 123, 124, 125, 126, 127 A9a
H629 Not done A3/A5
H631 133, 134, 135, 136 Undeterminedb
A2140 Not done A1/W11
A2147 7-1, 7-4 A4a
a Only one ELA-A type was detected with the antisera used (A1–A10
and W11).
b Undetermined indicates that none of the available antisera reacted with
lymphocytes from this horse.
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subtype C isolates have low amino acid diversity in Gag
CA protein, and infected patients have an immunodomi-
nant CTL response to this protein (Novitsky et al., 2002).
EIAV Gag MA and CA proteins are the most abundant and
conserved viral proteins (Montelaro et al., 1993) and are
also the most frequently recognized viral proteins by CTL
from longtime inapparent carrier horses infected with
EIAVWSU5 (McGuire et al., 2000). CTL from EIAV carrier
horses with diverse MHC class I alleles recognize epitope
clusters (EC) in Gag MA and CA proteins (Chung et al.,
2004). Three of four EC are recognized by CTL from
>50% of horses with diverse MHC class I alleles (Chung et
al., 2004). Two of these EC are from relatively conserved
regions of Gag MA and CA proteins. CTL with high
functional avidity to such conserved EC could be important
in controlling viral load in EIAV carrier horses.
During the acute phase of SIV infection, epitopes
recognized by CTL with high functional avidity escaped,
and it was hypothesized that such CTL were more
effective than CTL that did not select epitope change
(O’Connor et al., 2002). The functional and structural
constraints on particular viral regions may also influence
the rate of CTL escape because mutations in those regions
may result in replication defective variants (Matano et al.,
2004). In EIAV-infected horses, results suggest that the
epitope specificity of high and moderate functional avidity
CTL is an important determinant for disease outcome
(Mealey et al., 2003). Therefore, the functional avidity of
CTL from EIAV carrier horses to optimal epitopes in
relatively conserved Gag EC was evaluated.
In this study, optimal CTL epitopes in Gag EC were
mapped in order to determine the functional avidity of
CTL from nine long-term EIAV carrier horses that were
initially used to identify the EC. Since all the horses had
been infected for 526 days and there had been no clinical
episode for 167 days, the hypothesis was that carrier
horses would have high avidity CTL to optimal epitopes in
Gag EC. Surprisingly, the nine horses separated into two
groups: five with high functional avidity CTL to optimal
EC epitopes and four with low avidity CTL. Since the
specificity of the entire EIAV-specific CTL responses was
not mapped, it is possible that high avidity CTL were
present in all the horses to epitopes in proteins other than
Gag. When viral RNA could be amplified from EIAV-
infected horse plasma, it was sequenced and evaluated for
CTL escape variants. CTL escape variants were detected in
three horses, but only one variant epitope was recognized
by CTL with high functional avidity. Conserved EC3 had
the most optimal epitopes recognized by high functional
avidity CTL. That four carrier horses had CTL to Gag
EC with low functional avidity did not support the
hypothesis; however, those horses with high functional
avidity CTL had significantly more days since the last
clinical episode than horses with low functional avidity
CTL.Results
Mapping optimal CTL epitopes in Gag MA and CA EC
EC were previously identified using CTL from 12 EIAV-
infected horses and target cells pulsed with overlapping
15–16 amino acid peptides (Chung et al., 2004). In this
paper, 9 of the 12 horses were still available for use
including six with unique MHC class I alleles (Table 1). To
define optimal CTL epitopes, PBMC from each horse were
stimulated with a pool of 15–16 amino acid peptides that
were recognized by CTL from that horse (Chung et al.,
2004) and evaluated with autologous EK target cells pulsed
with truncated versions of the recognized peptides. Based
on comparison of percent specific lysis and peptide pulsing
concentrations, a total of 24 optimal epitopes were mapped
in MA and CA proteins (Fig. 1). One to seven optimal
epitopes were identified by CTL from each of the nine
horses (Table 2). These optimal epitopes ranged in length
from 8 to 12 amino acids, with 12 of 24 epitopes being 12
amino acids (Table 2).
It was of interest to evaluate the number of optimal
epitopes that occurred in the previously described EC (Fig.
2). EC1 contained two optimal epitopes recognized by CTL
from three horses, EC2 contained six recognized by four
horses, EC3 contained seven recognized by four horses, and
EC4 contained seven recognized by three horses (Fig. 2 and
Table 3). There were two optimal epitopes located in two
non-EC regions recognized by CTL from one horse each
(Table 3).
Functional avidity of CTL recognizing optimal epitopes
To determine the functional avidity, PBMC from each
horse were stimulated with a pool of 15–16 amino acid
peptides (final concentration of each peptide 103 nM)
recognized by CTL from each horse. They were tested for
recognition of EK cell targets pulsed with 100 to 104 nM of
Fig. 1. Distribution of optimal epitopes in Gag EC recognized by CTL from
nine EIAV-infected horses. Horse numbers in boxes had high functional
avidity CTL (11 nM) to the epitope.
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each horse. Representative data of a high functional avidity
CTL and data from the moderate functional avidity CTL areTable 2
Optimal Gag MA and CA epitopes recognized by CTL from EIAV-infected hors
Horse no. Optimal epitopes Gag location
H593 DCTSEEMNAF CA 47–56
KSEGHPQEISKF CA 173–184
H596 KMGLQINNVVDG MA 86–97
YPEFVDRLLSQI CA 161–172
FVDRLLSQIKSEa CA 164–175
IKSEGHPQEI CA 172–181
H601 GSQKLTTGNCNW MA 21–32
H610 YEKKTANK MA 108–115
MRHLRPEDTL CA 202–211
RPEDTLEEKMYA CA 206–217
EDTLEEKMYACR CA 208–219
YACRDIGTTKQK CA 216–227
H614 DRLLSQIKSE CA 166–175
H629 NEECRNAMRHLR CA 195–206
IGTTKQKMM CA 221–229
H631 KALKKLEKV MA 9–17
RAKYEKKTANK MA 105–115
A2140 GSQKLTTGNCNW MA 21–32
A2147 RTWWAISAVK MA 77–86
WWAISAVKMGL MA 79–89
WAISAVKMGLQI MA 80–91
GIKVMIGKPKAQ CA 140–151
PEFVDRLLSQ CA 162–171
RLLSQIKSEG CA 167–176
TLTIQNANEECRb CA 188–199
a Peptide EFVDRLLSQIKS was also recognized by CTL from H596 with h
FVDRLLSQIKSE.
b Only C-terminal eight amino acid residues of TLTIQNANEECR were in EC4in Fig. 3. Only five of nine carrier horses had CTL with high
functional avidity (11 nM peptide, Table 2), whereas the
other four horses had CTL with low functional avidity
(>1000 nM peptide, Table 2). The CTL with the highest
functional avidity (0.9 nM) were from horse H596 which
recognized autologous EK cell targets pulsed with an
optimal ten amino acid CA epitope (IKSEGHPQEI) (Table
2). Two other optimal epitopes were recognized by high
avidity CTL from horse H596 (2.7 and 9.9 nM, Table 2).
High functional avidity CTL from four other horses (H593,
H631, A2140, and H601) recognized one optimal epitope
each. Horse H631 also had CTL that recognized an optimal
epitope with moderate functional avidity (71.3 nM). Among
the six unique epitopes recognized by high avidity CTL
(11 nM), four were 12 amino acids long, and two were 11
and 10 amino acids long (Table 2).
High functional avidity CTL recognition of optimal epitopes
in EC
EC1–4 were evaluated to determine the number of
optimal epitopes recognized by high functional avidity CTL
(11 nM). EC1 contained one optimal epitope recognized
by high functional avidity CTL from horses A2140 and
H601, and EC2 contained one optimal epitope recognized
by high avidity CTL from horse H631 (Table 3, in
parentheses). High functional avidity CTL from horse
H593 recognized one EC3 epitope, whereas high avidityes
(name) Epitope cluster Avidity (nM)
(DF10) Non EC >1000
(KF12) EC3 3.7
(KG12) EC2 >1000
(YI12) EC3 2.7
(FE12) EC3 9.9
(II10) EC3 0.9
(GW12) EC1 10.9
(YK8) EC2 >1000
(ML10) EC4 >1000
(RA12) EC4 >1000
(ER12) EC4 >1000
(YK12) EC4 >1000
(DE10) EC3 >1000
(NR12) EC4 >1000
(IM9) EC4 >1000
(KV9) EC1 71.3
(RK11) EC2 7.9
(GW12) EC1 3.9
(RK10) EC2 >1000
(WL11) EC2 >1000
(WI12) EC2 >1000
(GQ12) Non EC >1000
(PQ10) EC3 >1000
(RG10) EC3 >1000
(TR12) EC4 >1000
igh functional avidity (10 nM) but was considered the same epitope as
(Chung et al., 2004).
Fig. 2. Multiple alignments of variant Gag MA and CA protein sequences identified from EIAV-infected carrier horses H610, H614, and H631. Underlined are
optimal peptide sequences recognized by CTL from each horse. In parentheses, following the horse number and sequence designation are the number of clones
with that sequence/total number of clones sequenced from each horse.
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EC4 nor the non-EC regions had epitopes recognized by
CTL with high functional avidity (Table 3). Therefore,
conserved EC3 (Chung et al., 2004) had the most optimal
epitopes recognized by high functional avidity CTL.Amino acid sequence variation in Gag MA and CA optimal
CTL epitopes in plasma virus from carrier horses
EIAV Gag RNA amplification from plasma by RT-PCR
was attempted in all but successful in only three of the nine
Table 3
Number of CTL epitopes in EC and non-EC regions and the number (in
parentheses) recognized by CTL with high functional avidity (11)
EC1 EC2 EC3 EC4 Non-ECa
2b (1b) 6 (1) 7 (4c) 7 (0) 2 (0)
a Non-EC indicates epitopes in regions outside EC1–4 (Chung et al.,
2004).
b One of these two epitopes was recognized by CTL from two horses
sharing an ELA-A haplotype.
c This number includes one epitope recognized by CTL from horse H593
and three epitopes recognized by CTL from H596.
C. Chung et al. / Virology 342 (2005) 228–239232EIAV carrier horses during this study. DNA sequences of
ten clones from each amplified product were evaluated to
determine if variation occurred in optimal CTL epitopes.
Two types of variant Gag sequences from horse H610 were
found among the ten clones (Fig. 2). All ten clones had one
amino acid change in MA epitope YK8 recognized by horse
H610 CTL, whereas there were no changes in the four
overlapping CA epitopes (Fig. 2). The ten clones from horse
H631 plasma had three variant Gag sequences; however, all
ten had one amino acid change in each of the two MA
epitopes (KV9 and RK11) recognized by horse H631 CTL
(Fig. 2). The ten clones from horse H614 plasma contained
eight variant Gag sequences, and three of these sequencesFig. 3. Representative data used for determining CTL functional avidity.
Panel A contains data from high avidity H631 CTL (EC50 = 7.9) stimulated
with peptide RK11 and evaluated on EK cell targets pulsed with different
concentrations of RK11. Panel B contains data from moderate avidity H631
CTL (EC50 = 71.3) stimulated with peptide KV9 and evaluated on EK cell
targets pulsed with different concentrations of KV9.representing a total of four clones had a single amino acid
change in epitope DE10 which was the only epitope
recognized by CTL from H614 (Fig. 2). The other six
clones had no amino acid changes in epitope DE10 (Fig. 2).
Surprisingly, all of the amino acid changes identified in
optimal epitopes were clearly conservative changing lysine
(K) to arginine (R) or vice versa (Table 4). The K in position
three of epitope YK8, recognized by CTL from horse H610,
was replaced with R in all 10 Gag sequences (Table 4). The
R in position two of CTL epitope DE10 was changed to K
in only four of ten clones from horse H614 plasma (Table
4). The K in position four of CTL epitope KV9 and the K in
C-terminal position 11 of CTL epitope RK11 were both
changed to R in all 10 clones from horse H631 plasma
(Table 4).
One conservative amino acid change in three different Gag
epitopes resulted in CTL escape
To determine whether the amino acid changes in Gag
epitopes recognized by CTL resulted in escape variants,
PBMC were stimulated with wild-type or variant peptides
and evaluated using EK cell targets pulsed with different
concentrations of these peptides. Horse H610 CTL stimu-
lated with peptide YK8 significantly lysed EK cells pulsed
with YK8, but not EK cells pulsed with variant peptide
vYK8 (Fig. 4). Furthermore, CTL stimulated with vYK8 did
not significantly lyse EK cells pulsed with either YK8 or
vYK8 peptide. Therefore, the KY R change at position 3 in
YK8 resulted in escape from horse H610 CTL, even though
these CTL had low functional avidity (>1000 nM, Table 2).
A one amino acid change occurred in wild-type FQ16
(FVDRLLSQIKSEGHPQ) peptide used for initial CTL
detection with PBMC from horse H614. CTL stimulated
with either FQ16 or vFQ16 failed to lyse EK targets pulsed
with vFQ16, whereas CTL stimulated with FQ16 signifi-
cantly lysed EK targets pulsed with FQ16, but not those
pulsed with vFQ16 (Fig. 5). The optimal epitope in FQ16
was DE10 (DRLLSQIKSE), but CTL escape of this optimal
epitope was not determined due to euthanasia of horse H614
following a clinical problem unrelated to EIAV infection.Table 4
Gag MA and CA CTL epitope variant in virus sequences from carrier horse
plasma
Horse
no.
No. of
sequences
with epitope
variant/total
Epitopes and location Epitope variant and
amino acid change
H610 10/10 YK8 (YEKKTANK),
MA 108–115
vYK8 (3K Y R)
H614 4/10 DE10 (DRLLSQIKSE),
CA 166–175
vDE10 (2R Y K)
H631 10/10 KV9 (KALKKLEKV),
MA 9–17
vKV9 (4K Y R)
H631 10/10 RK11 (RAKYEKKTANK),
MA 105–115
vRK11 (11K Y R)
Fig. 4. CTL escape by vYK8 peptide from horse H610 CTL recognizing
wild-type peptide YK8. The peptides used to stimulate PBMC and for
pulsing EK cell targets are listed in the legend. Bars above the data points
are SEs.
Fig. 6. CTL escape by vKV9 peptide from horses H631 CTL recognizing
wild-type KV9 peptide. The peptides used to stimulate PBMC and for
pulsing EK cell targets are listed in the legend. Bars above the data points
are SEs.
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peptide caused escape from horse H614 CTL, it is likely that
this change in position two of optimal epitope DE10 had a
similar effect.
CTL from horse H631 stimulated with optimal epitope
KV9 (KALKKLEKV) recognized EK cell targets pulsed
with KV9; however, there was no recognition of targets
pulsed with vKV9 (4K Y R) (Fig. 6). Moreover, there was
no recognition of targets pulsed with either KV9 or vKV9
when the effectors were stimulated with vKV9 (Fig. 6).
Thus, a conservative amino acid change in three different
Gag epitopes resulted in CTL escape in three different
EIAV-infected horses. For horse H614, this resulted in loss
of Gag recognition by CTL because only a single Gag
epitope was recognized; however, only four of ten clones
sequenced had the variant epitope (Table 4). Horse H610
had plasma virus with variation in one epitope that resulted
in CTL escape; however, CTL responses to Gag wereFig. 5. CTL escape by vFQ16 peptide from horse H614 CTL recognizing
wild-type FQ16 peptide. The peptides used to stimulate PBMC and for
pulsing EK cell targets are listed in the legend. Bars above the data points
are SEs.maintained in this horse because other Gag epitopes that did
not change were still recognized. Plasma virus variants from
horse H631 had changes in both optimal epitopes recog-
nized in Gag protein; KV9 was described in this section and
RK11 was described in the next section.
Clinical disease parameters in EIAV-infected horses with
high functional avidity CTL
To determine whether high functional avidity CTL
responses to Gag epitopes were related with virus control
in the nine EIAV-infected horses, the number of days since
the last clinical episode and RNA copies/ml plasma were
evaluated (Table 5). The five horses with CTL recognizing
Gag MA or CA optimal epitopes with high functional
avidities (11 nM) had significantly more days since the
last clinical episode (P < 0.05) than the four horses with lowTable 5
Number of CTL epitopes recognized and clinical disease episodes
Horse
no.
No. of
CTL
epitopes
No. of
epitopes
recognized
by high
avidity CTL
(11 nM)
Days
post-
infection
Days since
last clinical
episode
Viral RNA
copies/ml
plasma
H593 2 1 1651 952 <10
H596 4 3 845 781 40
H601 1 1 845 605 <10
H631 3 1 692 692 17
A2140 1 1 1748 1402
Mean 885
(315 SD)
<10
H610 5 0 692 447 <10
H614 1 0 832 482 27,090
H629 3 0 526 511 <10
A2147 7 0 1367 167
Mean 402
(158 SD)
<10
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between the days post-infection in the horses with high
functional avidity CTL and those with low avidity CTL (P >
0.05), indicating that having CTL with high functional
avidity was not simply a matter of being infected with EIAV
for a longer time (Table 5). The standard deviations for the
means of the two groups did not overlap (Table 5).
Furthermore, there was no significant difference in the total
number of epitopes recognized between horses with high
and low functional avidity CTL (P > 0.05). When all nine
horses in Table 5 were considered, there was a significant
inverse correlation (P < 0.05) between the number of days
since the last clinical episode and CTL avidity to Gag
peptides with a Spearman’s rank correlation coefficient of 
0.81. The rank correlation coefficient of0.45 between days
post-infection and CTL avidity was not significant (P >
0.05). In plasma samples obtained 1 month after the CTL
avidity was determined, the only horse with a relatively high
number of viral RNA copies/ml was horse H614 (Table 5).
This horse had low functional avidity CTL to a single Gag
epitope which varied and escaped CTL recognition.Discussion
Most HIV-1-infected humans ultimately have immuno-
deficiency leading to death from opportunistic infections
and malignancy (Sleasman and Goodenow, 2003). In
contrast, most EIAV-infected horses control the viremia
and clinical disease episodes within the first year of
infection by specific lymphocyte immune responses includ-
ing CTL (Mealey et al., 2001; Perryman et al., 1988).
Therefore, the mechanisms EIAV-infected horses use for
controlling viral load are of interest. The presence of CTL
correlates with control of the initial viremia in infected
horses (McGuire et al., 1994), whereas neutralizing anti-
body appears later (Carpenter et al., 1987; Montelaro et al.,
1984; O’Rourke et al., 1988). Furthermore, CTL to Gag
protein epitopes occur in most infected horses and are
present in sufficient numbers in carriers to be involved in
virus control (Chung et al., 2004; McGuire et al., 2000).
Both the quantity and quality of Gag CTL responses could
be important for controlling clinical disease episodes in
EIAV carriers. CTL responses to several Gag epitopes could
effectively control viremia because escape mutations would
have to occur in all the recognized epitopes for a loss of
viral control. Alternatively, high functional avidity CTL to a
small number of relatively conserved epitopes could
effectively control virus.
In this study, CTL from nine horses that had diverse
MHC class I alleles and that had controlled clinical disease
episodes for variable periods were used to identify optimal
CTL epitopes in previously defined Gag EC. These optimal
epitopes were then used to evaluate the functional avidity of
the responding CTL. Twenty-four optimal epitopes were
identified, but only six were recognized by high avidityCTL (11 nM); four were in conserved EC3 with three
recognized by CTL from one horse (H596). Though there is
support for either specificity or avidity being most important
in antiviral CTL responses (Alexander-Miller et al., 1996;
Derby et al., 2001; Yang et al., 2003), it may be that high
avidity CTL responses to epitopes in relatively invariant
sequences like EC3 may provide the most effective
lentivirus control. CTL recognition of epitopes in a func-
tionally important region would restrict the number of
mutations resulting in viable virus and thereby the number
of CTL escape variants. Therefore, immunization of horses
with more conserved EC3 and other EC with similar
properties may induce high avidity CTL to epitopes that
vary less. Vaccine vectors expressing relatively small EC
from minigenes could result in a marked increase in
peptide–MHC class I formation and stimulate CTL more
effectively (Anton et al., 1997). Using small EC might avoid
problems caused by using full-length proteins which include
stimulation of less effective CTL and of immune responses
that cause adverse effects (Raabe et al., 1998; Wang et al.,
1994; Woodberry et al., 1999).
EIAV-infected horses have recurrent episodes soon after
infection that may be associated with CTL escape variants
as variation in a SU epitope resulted in escape from CTL
(Mealey et al., 2003). Variation has been detected in EIAV
Gag CTL epitopes, but there is no direct evidence that this
resulted in escape from CTL (Mealey et al., 2003; Zhang et
al., 1998). In the current study, CTL escape variants were
identified from plasma viral RNA obtained from three of the
nine horses. The Gag protein epitopes that varied were
recognized by high (7.9 nM), moderate (71.3 nM), or low
(>1000 nM) functional avidity CTL. The high and moderate
avidity CTL recognizing epitopes that varied (KV9 and
RK11) were from horse H631. RK11 was the only epitope
among six recognized by high functional avidity CTL that
varied in this study. No viral sequences could be detected in
plasma from the other four horses with high avidity CTL
preventing further evaluation of possible escape from CTL.
In SIV-infected macaques, CTL escape occurs in epitopes
recognized by high avidity CTL during acute infection
(O’Connor et al., 2002). The major difference in this horse
study was that the high avidity CTL were identified in
carrier horses with relatively long-term infection and no
detectable viremia.
The horses in this study segregated into two groups
depending on whether they had high functional avidity
CTL to Gag protein epitopes or not. There were five horses
in the group that had high avidity CTL (11 nM);
furthermore, one of these horses (H631) also had the only
moderate avidity CTL (71.3 nM) to another epitope. The
other group of four horses all had low avidity CTL (>1000
nM). Thus, the hypothesis that all the carrier horses would
have high avidity CTL to optimal epitopes in the EC was
not supported by these data. Since the horse groups were
clearly segregated, it was of interest to see if clinical
disease patterns varied between the two groups. The
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infection of these horses was not considered because it
happened at a time when virus was obviously not
controlled. Thus, another parameter, the number of days
since the last clinical disease episode, was used in the
analysis. The group with high functional avidity CTL had
significantly more days since the last clinical episode than
the group with low functional avidity CTL. However, high
avidity CTL were not significantly associated with time of
EIAV infection, suggesting that their induction was not
time-dependent in these long-term carrier horses. Further-
more, when all nine horses were considered, there was a
significant (P < 0.05) inverse correlation between the days
since the last clinical episode and CTL avidity to Gag
peptides. The significant association between high avidity
CTL and less recent clinical disease episodes was
remarkable since the horses had been infected for different
times and were infected with different virus strains. It was
expected that such heterogeneity would obscure any
significant differences; even so, it will be necessary to
repeat this potentially important observation.
The effectiveness of high functional avidity CTL in viral
immune control is documented in mice models using
LCMV (Ehl et al., 1997; Gallimore et al., 1998; Speiser et
al., 1992), HIV-1 (Derby et al., 2001), and paramyxovirus
simian virus 5 (Gray et al., 2001). Adoptive transfer of
high or low functional avidity CTL into SCID mice
demonstrated that high avidity CTL were 100- to 1000-
fold more efficacious at clearing of vaccinia virus express-
ing HIV-1 gp160 than the low functional avidity CTL
(Alexander-Miller et al., 1996). The association of high
functional avidity CTL with control of EIAV episodes is
different from a recent study demonstrating that in vitro
inhibition of viral replication was more dependent on the
epitope specificity than functional avidity (Yang et al.,
2003). It is likely that CTL responses to particular epitopes
are critical for lentiviral control (Mealey et al., 2003; Yang
et al., 2003), however, CTL with high functional avidity to
these epitopes should be more effective than CTL with low
functional avidity. Another parameter that may be impor-
tant is the number of viral epitopes recognized by CTL.
CD4+ cell counts from HIV-1-seropositive patients were
positively correlated with the number of HIV-1 viral
peptides recognized by CTL, but not with the intensity of
anti-HIV CD8+ CTL responses (Dalod et al., 1999).
However, there was no significant difference in the number
of Gag epitopes recognized by CTL from EIAV-infected
horses in the high and low functional avidity groups in the
current study.
A higher importance of CTL quality over quantity was
suggested by the presence of high avidity CTL responses to
only a single Gag epitope or a few epitopes in EIAV carrier
horses with long-time clinical quiescence. CTL with high
functional avidity require extremely low epitope concen-
tration for recognition and may cause early lysis of infected
target cells. HIV-1 Gag epitopes have been described whichappear to be conserved because of constraints on variation
due to involvement of the amino acids comprising the
epitope in viral function (Goulder and Watkins, 2004).
Furthermore, epitope mutations in conserved regions with
functional constraint will result in viruses with decreased
replication capacity and consequently decreased clinical
disease (Friedrich et al., 2004; Kelleher et al., 2001).
Stimulating CTL to these relatively invariant epitopes could
stabilize CTL responses controlling virus replication and
slow down or even prevent disease progression (Nowak et
al., 1995). EIAV EC3 may be an example of such a region
because mutations in a similar area of HIV-1 CA protein
result in nonviable virus (Dorfman et al., 1994; Gitti et al.,
1996; Momany et al., 1996; Zhang et al., 1996).
Conclusively, the number of optimal epitopes in four Gag
CTL EC was determined, and the functional avidity of CTL
recognizing these epitopes was evaluated. Even though all
the EIAV carrier horses did not have high functional avidity
CTL to Gag EC, those that did had significantly more days
since the last clinical episode. In addition, there was a
significant inverse correlation between the functional
avidity of CTL and the days since the last clinical episode.
CTL escape was documented in Gag protein epitopes from
three horses, but only one of these was recognized by CTL
with high functional avidity. Conserved EC3 had the most
epitopes recognized by high functional avidity CTL, and
this and similar regions can be used to induce CTL in horses
with diverse MHC class I alleles. If protective CTL can be
induced, it will help define the requirements for CTL to be
protective against lentiviruses.Materials and methods
EIAV-infected horses
The nine infected horses used in this study (Table 1) were
previously inoculated with either EIAVWSU5 or EIAVPV and
were used to initially identify EC recognized by CTL
(Chung et al., 2004). Therefore, their use to identify CTL
epitopes in the EC was appropriate. The origin of EIAVPV
has been described (Rwambo et al., 1990). EIAVWSU5
(GenBank accession no. NP_056901) and EIAVPV (Gen-
Bank accession no. AAC03760) have identical Gag MA and
CA protein sequences. Autologous EK cells for CTL targets
were obtained from kidney biopsies prior to infection of
each horse and maintained as frozen cell lines (McGuire et
al., 1994). The MHC class I ELA-A haplotypes of the
horses used in this study were evaluated by lymphocyte
microcytotoxicity to determine the ELA-A types using
antisera A1–A10 and W11 (Table 1) (Bailey et al., 2000;
Bernoco et al., 1987; Lazary et al., 1988; Terasaki et al.,
1978). Furthermore, the MHC class I alleles of six of the
nine horses (H593, H596, H610, H614, H631, A2147) were
previously determined by sequence-based typing (Table 1)
(Chung et al., 2003).
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EC were identified using 52 previously described
peptides of 15 amino acids overlapping by 11 amino acids
and 21 peptides of 16 amino acids overlapping by 12 amino
acids with C-terminal OH and N-terminal H groups cover-
ing the entire EIAV Gag MA and CA proteins (Chung et al.,
2004). For fine mapping of epitopes within the 15–16
amino acid peptides significantly recognized by CTL,
additional peptides of 8–15 amino acids were synthesized
(Sigma-Genosys, The Woodlands, TX). The peptides were
dissolved in 100% dimethyl sulfoxide and stored at 20 -C
before dilution and use for CTL epitope mapping.
PBMC isolation and stimulation of memory CTL for CTL
assay
PBMC were isolated from the EIAV-infected horses by
centrifugation on Histopaque (specific gravity 1.077),
washed four times, and viability determined (Wyatt et al.,
1988). Monocytes in PBMC were infected with EIAVWSU5
at a multiplicity of infection of one or incubated with
peptides (103 nM final concentration) in 5 ml of RPMI 1640
with 20% FCS at 37 -C for 2 h with gentle mixing every 15
min (McGuire et al., 2000; Zhang et al., 1998). Stimulations
were done in a 175 cm2 tissue culture flask containing
RPMI 1640 with 10% fetal calf serum, 5  105 M 2-
mercaptoethanol, and 20 mM Hepes. After incubation in a
humidified chamber with 5% CO2 at 37 -C for 7 days,
viable lymphocytes were counted using exclusion of trypan
blue dye in a hemocytometer for use in the 51Cr release
assay (McGuire et al., 2000).
CTL assay
The 51Cr release assay was used to identify peptides
recognized by CTL from EIAV-infected horses. EK target
cells (3  104/well) were incubated in collagen-coated wells
of 96-well plates at 37 -C with 5% CO2 for 24 h before
labeling with 1.25 ACi of 51Cr and pulsing with 104 nM
synthetic peptides in 50 Al per well of DMEM containing
5% fetal calf serum at 37 -C for 2 h. After washing three
times with DMEM, effectors were incubated with target
cells (effector-to-target cell ratio of 50:1) in 200 Al/well
RPMI containing 10% fetal calf serum at 37 -C with 5%
CO2 for 17 h (McGuire et al., 1994). Then, 100 Al of
supernatant was removed from each well to determine 51Cr
release. Percent specific lysis was calculated as [(E  S)/
(M  S)]  100, where E was the mean of three test wells,
S was the mean spontaneous release from three wells
without effector cells, and M was the mean maximal release
from three wells with 2% Triton X-100. The standard error
(SE) of percent specific lysis was calculated taking into
consideration the variability of E, S, and M as described
previously (Siliciano et al., 1985). Only assays with a
spontaneous lysis of <30% were used. Specific lysis ofpeptide-pulsed target cells that was >10% and exceeded
lysis of non-pulsed target cells by >2.5 SE was considered
significant.
CTL functional avidity
The functional avidity of CTL was determined by
stimulating PBMC with pools containing 103 nM of each
optimal peptide epitope. CTL assays were then performed
using target cells pulsed with 10-fold dilutions of peptides
ranging from 100 to 104 nM, and functional avidity was
calculated (Mealey et al., 2003). CTL functional avidity
was defined as the peptide concentration (nM) that
resulted in 50% maximal target cell specific lysis and
was used to describe the effectiveness of CTL-mediated
killing, encompassing TCR affinity and signaling, as well
as the affinity of MHC–peptide binding (Alexander-Miller
et al., 1996; Derby et al., 2001). Functional avidity was
not determined if the maximal specific lysis of peptide-
pulsed target cells was less than 10% above the specific
lysis of non-pulsed target cells. CTL were considered to
have high functional avidity if the peptide concentration
resulting in 50% maximal lysis was 11 nM. This cut-off
for high avidity was based on data being in three groups
including 7 avidities ranging between 0.9 and 10.9 nM,
one of 71.3 nM, and the remaining 17 were >1000 nM
(Table 2). The high avidity cut-off of 11 nM is similar to
the <5 nM cut-off used by others (Mealey et al., 2003;
O’Connor et al., 2002). In the assays of CTL with high
and moderate avidity, maximal lysis was reached expedit-
ing the calculations of avidity. In the cases of those CTL
designated as having low avidity, it was not certain
whether maximum lysis was obtained with 10,000 nM
peptide or not. In those cases, the results at 10,000 nM
were assumed to be maximal, and the EC50 was
calculated. The EC50 was always >1000 nM, and this
value was used as a minimum estimate of the EC50 for
the low avidity CTL.
Cloning and sequencing of Gag MA and CA
Viral RNA amplification was attempted from all nine
carrier horses but was successful in only three. Viral RNA
was isolated using a QIAamp Viral RNA kit (Qiagen Inc.,
Chatsworth, CA) (Leutenegger et al., 2001) with 0.14 ml
frozen EDTA plasma from horses H610 and H614 and 1.4
ml from H631. RNA was treated with DNase I on the spin
column (DNase 1 set; Qiagen), eluted in 60 Al nuclease-free
water, and frozen at 20 -C. First-strand cDNA was made
using a primer (5VTGTCCTGGCTTCCCACAG) and a
cDNA synthesis system (Invitrogen, Carlsbad, CA) with
an annealing temperature of 42 -C. The first PCR was
carried out in 25 Al reactions with 1.2 mM MgCl2, 0.5 mM
of each dNTP, 10 Amol of each primer (forward:
5VACAGAAGTCTTCTGGAGG3V, reverse: 5VCTTTAGQ
TGGCCCTCCTTT3V), and Taq DNA polymerase (Invitro-
C. Chung et al. / Virology 342 (2005) 228–239 237gen, Carlsbad, CA). Thirty-five cycles were done at 95 -C
(30 s), 53 -C (30 s), and 72 -C (1 min), with a last
extension reaction at 72 -C for 7 min. A second PCR was
done with a nested primer set (forward: 5VTCTTCTQ
GGAGGTGTTCCTGG3V, reverse: 5VCTTTAGTGGCCCQ
TCCTTT3V) using the same conditions as in the first
PCR.
Amplified DNA was separated on a 1% agarose gel
(BioWhittaker Molecular Applications, Rockland, ME) for
2 h at 60 V in 0.04 M Tris–acetate buffer with 0.001 M
EDTA. Bands with the appropriate number of base pairs
were excised from the gel, and the DNA isolated using a gel
extraction kit (Qiagen). Purified DNA was ligated into the
Zero Blunt TOPO cloning vector (Invitrogen, Carlsbad, CA)
for 5 min at room temperature, transformed into competent
cells (Invitrogen), and plated on LB agar with 50 Ag/ml
kanamycin. Clones containing inserts of the predicted size
were identified first by PCR, and then 10 clones from each
amplification were selected for DNA sequencing using
automated sequencer (ABI 377, Amersham Biosciences,
Discataway, NJ). Thirteen variant EIAV Gag MA and CA
sequences (GenBank accession no. AY742243–AY742255)
obtained from the 3 horses, together with a published
EIAVWSU5 Gag sequence (GenBank accession no.
AF247394), were used for multiple alignments with
CLUSTAL W (Chenna et al., 2003).
Determination of plasma viral load by real-time RT-PCR
A previously described quantitative real-time RT-PCR
(Mealey et al., 2003) was used with modifications to
determine plasma viral load by amplification of a 167 base
pair segment (nucleotides 1637–1803) of the EIAVWSU5
(GenBank accession no. AF247394) gag gene. A standard
RNA template was made and the copy numbers determined
as described (Mealey et al., 2003). Primers 1637F
(5VAGCCAGGACATTTATCTAGTCAATGTAGAGCQ
ACC3V) and 1803R (5VGTGCTGACTCTTCTGTTGTQ
ATCGGGAAAGTTTG 3V), along with a previously
reported gag-specific probe (Cook et al., 2002), were used
in duplicate 25 Al reactions utilizing an iScript One-Step
RT-PCR kit for probes (Bio-Rad Laboratories, Hercules,
CA), 200 nM of each primer and probe, 40 U Rnasin, and
10 Al plasma RNA template. Reactions were done in an
iCyler with the iQ Real-Time PCR Detection System and
software (Bio-Rad) under the following conditions: 30 min
at 50 -C, 3.5 min at 95 -C, 50 cycles at 95 -C for 15 s, and
60 -C for 1 min. Sensitivity was determined using a dilution
series of the standard RNA transcripts. The dilutions
containing 1 RNA copy was positive in 40% (4/10) of the
replicates, while the dilutions containing 10 RNA copies or
more were positive in 100% (10/10) of the replicates. The
reliable detection limit, therefore, was somewhere between
43 and 428 RNA copies/ml when 140 Al plasma for the
RNA extraction and 10 Al of the 60 Al eluate were used
(Mealey et al., 2003).Statistical analysis
The total number epitopes recognized by CTL, the
number of days post-infection, and the number of days
since the last clinical episode (non-progression period) were
compared for horses with high functional avidity CTL and
those with low functional avidity CTL using the Mann–
Whitney U test. Significance was determined by P < 0.05.
In addition, a Spearman’s rank correlation coefficient was
determined for days since the last clinical episode and
avidity for all horses as well as the days post-infection and
avidity with significance determined by P < 0.05.Acknowledgments
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